The practical consequence is blunt: the same batch, analyzed by the same laboratory, producing identical data, can pass in one state and fail in another. Understanding cannabis testing regulations by state is not academic for anyone operating across markets.

Why the Patchwork Exists

Cannabis remains a federally controlled substance in the United States, which keeps the FDA and USDA out of the space in the way they operate for food, drugs and agricultural commodities. There is no federal agency setting methods, no federal action limits, and no federal accreditation requirement.

States filled the vacuum independently, at different times, drawing on different reference frameworks — some borrowed from food safety, some from pharmaceutical practice, some from environmental testing. Each was a reasonable choice. Together they produced a patchwork.

Where States Actually Differ

Which analytes are required

Every state requires potency and some contaminant testing, but the specifics vary widely. Pesticide lists range from a few dozen compounds to well over a hundred. Some states name specific microbial organisms; others rely on total counts. Terpene analysis is required in some markets and optional in most. Heavy metal panels usually cover the same four elements, though some add others.

Action limits

Even where two states screen for the same compound, the threshold can differ by an order of magnitude. Limits are set through different risk assessments, and there is no reference standard forcing convergence.

Analytical methods

Some states prescribe methods. Others specify outcomes and leave method selection to the laboratory. Prescribed methods reduce variation between laboratories; outcome-based rules allow flexibility and produce more spread. Both approaches are in use.

Sampling

Who takes the sample, how many increments, from what batch size, under what protocol — all of this varies. Since sampling is the largest single source of variability in a result, differences here matter more than they appear to. See the limits of current testing methods.

Batch size definitions

A state that permits large batches spreads testing cost across more product and exposes more product to a single failure. A state with tighter batch limits does the reverse. This has a direct effect on unit economics, covered in what cannabis testing costs.

Remediation

Whether a failed batch can be remediated and retested, and for which failure types, differs substantially. Some states permit remediation of microbial failures under defined conditions; others prohibit it entirely. Heavy metal and pesticide failures are generally not remediable anywhere, since the contaminant is in the material rather than on it.

Laboratory requirements

ISO/IEC 17025 accreditation is required in many states, including Missouri, and not in all. Proficiency testing requirements vary from mandatory blind programs to nothing at all. This is one of the clearer quality signals when comparing markets.

What This Costs Multi-State Operators

Operating across several markets means maintaining parallel compliance regimes for what is often the same product.

Products are frequently reformulated per market to meet different limits. Testing is duplicated because results are not portable across state lines — and neither is the product, since interstate transport remains federally prohibited. Labeling differs by market. Documentation systems have to track which rules apply where.

This is a significant part of why cannabis has not consolidated the way comparable industries have, and why some multi-state operators standardize internally to the strictest market they operate in. It is cheaper than maintaining genuinely separate systems, and it removes the risk of a product built to one standard ending up somewhere stricter.

Internationally, the Picture Is Different Again

Countries with medical cannabis frameworks have generally taken a different route from US states: rather than writing cannabis-specific rules from scratch, many have applied existing pharmaceutical quality standards.

Where cannabis is regulated as a medicine, Good Manufacturing Practice requirements typically apply, along with pharmacopoeial monographs that specify methods and limits. That produces a more rigorous and more standardized regime than most US state programs — with correspondingly higher production costs and slower routes to market.

Canada regulates federally, which means one set of rules nationwide and a level of consistency US operators do not have. Several European medical programs require pharmaceutical-grade production and EU-GMP certification. The contrast is instructive: it shows what a single national framework produces, which is the direction US federal reform would push. See where cannabis is legal around the world.

Where Convergence Is Coming From

Harmonisation is happening, slowly, without federal action.

Standards bodies — AOAC International, ASTM, the US Pharmacopeia — publish validated methods that states and laboratories can adopt. Newer state programs tend to copy from established ones rather than start fresh, which produces convergence by imitation. And multi-state operators standardising internally create de facto consistency ahead of regulation.

Federal reform would compress all of this. Rescheduling or descheduling would bring federal agencies into the space with a single set of methods and limits, in the way food and pharmaceutical testing already work. More in standardization and transparent reporting and the future of cannabis lab testing.

What Operators Should Do Now

• Know the rules where you sell, not where you produce. The market of sale governs.
• Build to the strictest standard you operate under. Cheaper than maintaining parallel systems, and it protects you if a market tightens.
• Do not assume results transfer. A COA from one market does not satisfy another’s requirements.
• Track rule changes actively. Analyte lists and limits are amended more often than most operators notice.
• Use a laboratory that understands your markets. A laboratory familiar only with one state’s rules will not flag a problem for another.

The post How Cannabis Testing Rules Differ Across States and Countries appeared first on TruMo Analytics.

What differs is the legal framework wrapped around them — and that framework changes who can buy, how much, at what price, with what protections, and in some jurisdictions under what testing requirements.

The Core Legal Distinction

Medical cannabis requires a physician’s recommendation and, in most programs, a state-issued patient license. The purchase is framed as treatment, and the patient is a registered participant in a program.

Recreational — or adult-use — cannabis requires only proof of age, usually 21. No physician, no registration, no medical framing.

Both remain illegal under United States federal law regardless of state status. That is the constant underneath every state framework, and it is why banking, interstate transport and federal employment issues affect both categories identically. See why dispensaries still operate in cash.

Where the Practical Differences Land

Purchase and possession limits

Medical patients typically have higher limits than adult-use consumers in states that run both programs. The reasoning is straightforward — a patient using cannabis daily for a chronic condition consumes more than an occasional user.

Potency caps

Several states cap potency for adult-use products, particularly edibles, while allowing higher concentrations for medical patients. This is one of the more common reasons a product exists in two versions.

Tax

Medical cannabis is generally taxed at lower rates. Some states exempt it from excise tax entirely. This is often the largest practical difference for a consumer, and it is why patient programs persist in states that have legalized adult-use.

Age

Adult-use is restricted to 21 and over. Medical programs admit minors with additional requirements — typically two physician recommendations and guardian consent.

Home cultivation

Where home growing is permitted, medical patients usually have higher plant limits than adult-use consumers.

Employment and legal protections

Some states extend employment protections to registered medical patients that do not apply to adult-use consumers — though the protections are narrower than most people assume, with carve-outs for safety-sensitive roles and no effect on federal employment.

Testing: Mostly the Same, Sometimes Not

In most states, medical and adult-use products go through the same testing regime. The contaminants are the same, the health risks are the same, and there is no coherent argument for testing one more rigorously than the other.

Where differences exist, they usually reflect the patient population rather than the product. Some medical programs require additional or more specific microbial screening, on the reasoning that immunocompromised patients face higher risk from fungal contamination — a genuine concern covered in the risks of untested cannabis products. Some require terpene or full cannabinoid profiling that is optional for adult-use, because patients dosing to a therapeutic target need more compositional detail.

Where potency caps differ by program, the compliance thresholds differ accordingly, even though the analysis is identical.

The panels themselves are described in types of cannabis testing.

Labeling Differences

Medical product labeling typically carries more information: full cannabinoid profile rather than THC alone, dosing guidance, patient-directed warnings, and in some programs the recommending physician’s details or program identifiers.

Adult-use labeling emphasises impairment warnings, serving sizes and the fact that effects can be delayed — particularly for edibles, where delayed onset is the most common cause of unintended overconsumption.

Missouri’s Position

Missouri runs both programs side by side. Medical cannabis was approved by Amendment 2 in November 2018; adult use followed with Amendment 3 in November 2022, with the first adult-use sales in February 2023. Unlike states that left eligibility entirely to the recommending physician, Missouri publishes a list of qualifying conditions — but that list ends in a catch-all that leaves the final call to the certifying provider’s professional judgment.

The practical differences that remain are real but narrow. Medical patients pay a 4 percent state excise tax against 6 percent on adult-use sales, plus any local adult-use levy. Patients may buy up to six ounces in a 30-day period and possess a 60-day supply; adult-use purchases and possession are capped at three ounces. Patients under 21 can participate through a parent or guardian acting as caregiver, which adult use does not allow. Both routes permit home cultivation with a state card, but the patient card costs less and runs up to three years against twelve months for the consumer card.

Why the Distinction Persists

In states with both programs, medical enrollment often falls after adult-use launches — patients who only needed access find the recommendation and registration no longer worth the trouble.

But medical programs persist, for reasons that are practical rather than symbolic: lower taxes, higher purchase and possession limits, higher potency ceilings, access for patients under 21, employment protections in some states, and a clinical relationship that supports informed dosing. That last point matters more than it is usually given credit for — the difference between a patient working with a clinician and a consumer working from a label is real, and it is covered in working with a qualified cannabis clinician.

For Operators

If you produce for both markets, the compliance requirements are usually parallel but not identical. Potency caps, labeling, packaging and occasionally testing panels differ, and a product built for one program is not automatically compliant in the other.

Build to the stricter standard where you can. It is cheaper than maintaining two production paths, and it removes the risk of product ending up in the wrong channel. For how requirements diverge across jurisdictions, see how testing rules differ across states.

The post Medical vs Recreational Cannabis: Law, Labeling and Testing appeared first on TruMo Analytics.

The Four Models

Full legalization. Adult-use cannabis is legal, regulated and taxed, with a licensed commercial supply chain. Uruguay was first, in 2013. Canada followed nationally in 2018. In the United States, a majority of states have legalized adult use while federal prohibition remains in place — a contradiction with real consequences for banking, transport and enforcement.

Medical-only frameworks. Cannabis is available by prescription or recommendation through a regulated system, with recreational use still prohibited. This is now the most common model. Germany, Australia, Israel, the United Kingdom, and a substantial number of other countries operate versions of it, though access varies from genuinely accessible to nominal.

Decriminalisation. Possession of small amounts is not a criminal offense, but supply remains illegal. Portugal is the widely cited example, having decriminalised all drug possession in 2001 and redirected resources toward treatment. Decriminalisation addresses criminal justice consequences without creating a legal supply, which is a meaningful difference.

Prohibition. Still the position in much of Asia, the Middle East and Africa, in some cases with severe penalties.

How Medical Access Differs in Practice

“Medical cannabis is legal” describes very different realities depending on where you are.

Some programs are broadly accessible — Missouri, for example, publishes a list of qualifying conditions but ends it with a catch-all that leaves the decision to the certifying provider’s professional judgment. Others restrict eligibility to a narrow set of conditions, usually after conventional treatments have failed, with specialist approval required. A few permit cannabis-derived medicines only for a handful of licensed indications, which is closer to pharmaceutical regulation than to a cannabis program.

The practical test is not whether a framework exists but how many patients actually receive product through it. On that measure, several countries with medical frameworks have very low real-world access.

What Legalization Does to Testing Standards

This is where the models diverge most sharply, and it is the part with direct consequences for product quality.

Countries that regulate cannabis as a medicine generally apply existing pharmaceutical standards — Good Manufacturing Practice, pharmacopoeial monographs specifying methods and limits, and full batch documentation. This produces a rigorous, standardized regime, with correspondingly high production costs and slow routes to market. Several European medical programs work this way.

Countries that regulate cannabis as its own category write bespoke rules. Canada does this federally, which gives it one consistent national standard. The United States does it state by state, which produces the patchwork described in how testing rules differ across states.

Decriminalised markets have no testing regime at all, because there is no legal supply chain to regulate. Consumers get the criminal-justice benefit without the product-safety benefit — which is a genuine limitation of the model, and the reason contamination risks in untested cannabis products persist there.

The International Treaty Layer

Cannabis is controlled under three United Nations conventions, principally the 1961 Single Convention on Narcotic Drugs. Countries legalizing adult use are therefore in tension with treaty obligations, which is part of why several have taken slower or more constrained routes than domestic politics alone would explain.

The 2020 reclassification of cannabis under the 1961 Convention — removing it from the schedule reserved for substances with no recognized medical value — was a meaningful signal, though it did not change any country’s obligations regarding non-medical use.

What Legalization Consistently Produces

Across markets that have legalized, several patterns recur reliably enough to be predictable.

An initial supply shortage, then oversupply. Almost every legalized market has followed this arc. Licensed production takes time to come online, then overshoots.

Price decline. Legal prices start above illicit prices, then fall — sometimes below them — as production scales.

Consolidation. Early markets fragment across many small operators; capital requirements and compliance overheads then favor scale.

Tightening regulation. Initial frameworks are usually revised toward stricter testing, labeling and marketing rules once problems surface. Requirements very rarely loosen.

Persistent illicit supply. Legal markets do not eliminate illicit ones, particularly where taxes are high or licensed retail is thin. Which means untested product remains in circulation even in mature legal markets.

Why This Matters Beyond Policy Interest

For operators, the international picture is the clearest available preview of where domestic regulation is heading. Markets that legalized earlier have already worked through the problems newer markets are encountering, and their responses — mandatory accreditation, standardized methods, blind proficiency testing, tighter marketing rules — are the likely template.

Pharmaceutical-grade frameworks in particular show what cannabis testing looks like when it is held to the standard applied to medicines. Some of that is already arriving in US state programs. More on the trajectory in the future of cannabis lab testing and the future of the cannabis industry.

For how the regulatory framework in the United States reached its current shape, see from the Marihuana Tax Act to Amendment 3.

The post Where Cannabis Is Legal Around the World appeared first on TruMo Analytics.

The underlying principle in every regulated market is the same: cannabis waste must be rendered unusable and unrecognisable before it leaves the licensed premises, and the whole process must be documented.

What Counts as Cannabis Waste

More than most operators initially account for.

• Plant waste — stalks, stems, fan leaves, root balls, and material removed during trimming
• Failed batches — product that did not pass testing and cannot be remediated
• Expired or unsaleable product, including returns
• Extraction by-products — spent biomass, filtration media, and material from failed runs
• Laboratory samples returned or retained beyond their retention period
• Contaminated packaging containing residual product
• Recalled product

Male plants removed from a grow, cuttings that did not root, and material lost to pests all fall into the same category. If it is cannabis and it is not going to be sold, it is waste and it has to be handled as waste.

Rendering Waste Unusable

The standard requirement is that cannabis waste be mixed with non-consumable material until it is no longer usable or recognisable as cannabis. Commonly accepted mixing materials include soil, compostable green waste, paper waste, cardboard, food waste and other non-hazardous solid waste. Rules usually specify a minimum ratio.

Some jurisdictions permit alternative methods — grinding and incorporation, composting on site, or incineration through a licensed facility. Chemical rendering is accepted in some markets and prohibited in others.

The point of the requirement is diversion. Unrendered cannabis waste in a skip is product that can be retrieved and sold outside the regulated system, and diversion is what waste rules exist to prevent.

Storage Before Disposal

Waste awaiting disposal is still cannabis and still subject to security requirements. In practice that means a designated, secured area within the licensed premises, containers that are labeled and closed, video coverage where the rules require it, and access restricted to authorised personnel.

Waste accumulating in an unsecured back room or an unmonitored yard is a finding waiting to happen, and it is one inspectors look for specifically.

Documentation Is the Part That Gets Cited

Most waste findings are documentation failures rather than disposal failures — the material was handled correctly and the record does not prove it.

A complete waste record generally covers:

• Date and time of disposal
• Type and weight or quantity of waste
• The batch or lot it came from
• Reason for disposal (failed testing, expired, trim waste, recall)
• Rendering method and mixing material used
• Final disposition — hauler, facility, or on-site composting
• Names and signatures of the employees who performed and witnessed it

Seed-to-sale tracking systems normally require waste to be recorded against the originating batch, and mismatches between physical waste records and tracking system entries are among the easiest discrepancies for an inspector to find.

Many jurisdictions also require advance notice before disposal, or a waiting period between recording waste in the tracking system and physically destroying it, precisely so that disposal can be observed.

Failed Batches Specifically

Failed material needs particular care because it is the category most likely to be diverted.

Quarantine it immediately and separately, clearly labeled. Do not return it to general inventory under any circumstance. Establish whether remediation is permitted for that failure type before deciding anything — microbial failures are sometimes remediable depending on the organism and method, while heavy metal and pesticide failures are not, because the contaminant is in the material rather than on it.

If remediation is not permitted or not successful, dispose of it as waste with full documentation, and investigate the cause. Each failure type points somewhere specific, mapped in contaminant testing explained. Disposing of a failed batch without finding out why it failed guarantees a second one.

The Environmental Side

Beyond compliance, waste is a real environmental cost that the sector is only starting to address.

Plant waste is compostable and, where rules permit on-site composting, can go back into growing media rather than to landfill. Packaging waste is a larger problem — child-resistant packaging requirements have driven the industry toward plastics that are difficult to recycle, and the volumes are substantial. Spent extraction media and single-use consumables add to it.

Operators reducing waste volume upstream — better yield from extraction, less over-packaging, reusable containers where permitted — cut both disposal cost and footprint. More in sustainability in cannabis cultivation.

Getting It Right

Write a documented waste procedure and train to it. Designate and secure a waste area. Log every disposal against its batch. Reconcile physical records against the tracking system on a schedule rather than before an inspection. Keep records for the full required retention period.

None of this is difficult. It is simply the kind of task that gets deferred until an inspector asks for twelve months of waste logs.

The post How Cannabis Processors Should Handle Waste Disposal appeared first on TruMo Analytics.

The short version: general roles have become harder to get, and technical roles have become easier.

Where the Work Is

Cultivation

Growing at commercial scale is horticulture with compliance attached. Roles run from trimmers and general growth technicians through to head grower, with integrated pest management and post-harvest processing as specialisms.

Entry is comparatively open — trimming and general labour need no formal qualification — but progression rewards horticultural knowledge, environmental control experience and an understanding of why plants do what they do. A head grower in a serious operation is running a production system, not tending plants.

Extraction and manufacturing

Turning biomass into concentrates and finished products. Extraction technicians, formulators, production operators, packaging supervisors.

This is where chemistry background transfers directly, and where safety training is non-negotiable — hydrocarbon extraction involves flammable solvents under pressure in a regulated environment. Formulation roles in infused products increasingly require food science alongside cannabis knowledge, because the analytical problems are food problems. See why edibles are tested differently.

Laboratory science

Analytical chemists, laboratory technicians, quality assurance and quality control staff, and laboratory managers.

These roles have the clearest transferable qualifications of anything in the sector. Experience with HPLC, GC-MS, LC-MS/MS or ICP-MS transfers directly from pharmaceutical, environmental or food testing — the instrumentation is the same, and the matrix is the part you learn on the job. A chemistry degree plus hands-on instrument experience is a strong position.

Demand here has held up better than almost anywhere else in the sector, because accreditation requirements have tightened rather than loosened. An ISO/IEC 17025-accredited laboratory needs demonstrably competent analysts, and that competence is assessed. What the work involves day to day is in the cannabis testing process.

Compliance and regulatory

Compliance managers, regulatory affairs specialists, quality systems staff, internal auditors.

This is arguably the most undersupplied area in cannabis. The rules are complex, they change, and they differ by jurisdiction — someone who genuinely understands their market’s regulatory framework and can build systems that satisfy it is difficult to replace. Backgrounds in regulated food, pharmaceutical or alcohol industries transfer well.

Retail

Dispensary associates, managers, inventory and purchasing.

The largest employer by headcount and the most accessible entry point. Good associates need real product knowledge — the difference between product formats, how onset differs, what a certificate of analysis actually says — because customers ask and the answers matter. Buyers who can read a COA properly are worth more than buyers who cannot.

Everything around it

Cannabis needs accountants who understand the tax position, lawyers who know the regulatory landscape, security specialists, logistics staff, marketing people who can operate under advertising restrictions, and software teams building seed-to-sale and compliance systems. These roles often pay better than operational ones and draw on skills that transfer both ways.

What the Market Correction Changed

In markets that have moved past expansion, hiring has shifted in a consistent direction.

General labour roles contracted along with the number of licensed cultivators. Technical roles held up, because the operations that survived tend to be the better-run ones, and better-run operations need laboratory analysts, extraction technicians and compliance managers regardless of market conditions.

The practical read: enthusiasm for the plant was a reasonable entry credential in 2019. It is not now. Demonstrable competence is.

What Actually Helps

Transferable technical skills. Analytical chemistry, horticulture at scale, food science, regulated manufacturing. These are assessable and they transfer in both directions, which also protects you if the sector contracts further.

Regulatory literacy. Knowing your market’s rules — not in general terms, but specifically — is rare and valuable. Reading your state’s regulations properly puts you ahead of most applicants.

Understanding testing. A surprising number of people in the industry cannot read a certificate of analysis. Being able to is useful in cultivation, extraction, purchasing and compliance alike. Start with reading lab results and types of cannabis testing.

A license or badge where required. Many states require worker registration or a background check. Having it already removes a delay for the employer.

What to Be Realistic About

Cannabis is a normal industry with unusual constraints. Pay in operational roles is comparable to similar work in other sectors rather than elevated. Job security tracks the market — and cannabis markets have proven volatile. Federal illegality has practical consequences for banking, benefits and anything requiring a federal clearance.

And there are structural equity issues the sector has not resolved, particularly around who holds licenses and who was affected by prohibition enforcement. That is covered in diversity, equity and inclusion in the cannabis industry.

None of that is an argument against the sector. It is an argument for entering it with the same expectations you would bring to any other regulated industry — and for building skills that are worth something regardless of what the market does next.

The post Careers in the Cannabis Industry appeared first on TruMo Analytics.

Cannabis as a Listed Medicine

Cannabis entered Western medicine substantially through William Brooke O’Shaughnessy, an Irish physician working in Calcutta in the 1830s. He studied its use in Indian medicine, conducted his own trials, and published on its application to conditions including rheumatism, tetanus and convulsions — including a case of infantile convulsions that drew considerable attention.

His work brought cannabis into British and then American medical practice. By the second half of the nineteenth century it was a standard pharmacy item, listed in the United States Pharmacopeia and sold by major pharmaceutical manufacturers as tinctures and extracts for pain, sleep, appetite and muscle spasm.

Its decline in medical use began before any legal restriction. Injectable opiates and, later, aspirin offered more predictable dosing — cannabis preparations varied enormously in strength, which is precisely the problem that potency testing exists to solve.

The 1937 Marihuana Tax Act

The federal turn came in 1937. The Marihuana Tax Act did not formally prohibit cannabis — it imposed a tax and a registration requirement on anyone dealing in it, with penalties for non-compliance severe enough that the practical effect was prohibition.

The legislative record around it is not edifying. The campaign leading to the Act relied heavily on sensational press coverage, and the terminology itself — “marihuana” rather than the cannabis familiar to physicians and pharmacists — did work that was partly deliberate. Racial politics of the period were explicitly present in the advocacy.

The American Medical Association opposed the Act, objecting both to the restriction on a medicine still in use and to the process by which it was passed.

Cannabis was removed from the United States Pharmacopeia in 1942. Within five years it went from a listed medicine to a substance most physicians could not practically prescribe.

The Controlled Substances Act

The Marihuana Tax Act was struck down in 1969 on constitutional grounds — the registration requirement compelled self-incrimination. Congress responded with the Controlled Substances Act of 1970, which placed cannabis in Schedule I: the category reserved for substances deemed to have high abuse potential and no accepted medical use.

Schedule I is the foundation of everything since. It is why cannabis research has been difficult to conduct, why federal agencies have no framework for regulating cannabis products, why banks avoid the sector, and why state programs exist in tension with federal law rather than under it. Practical consequences are covered in why dispensaries still operate in cash.

States Move First

Reform came from the states, and it came slowly.

California’s Proposition 215 in 1996 was the first medical cannabis program in the modern era. Over the following two decades a majority of states followed with medical frameworks, and from 2012 onward a growing number added adult-use legalization.

Each state built its own system — its own eligibility rules, licensing structure, product standards and testing requirements — because there was no federal framework to build on. That is the direct cause of the patchwork described in how testing rules differ across states.

The Case That Changed the Conversation

Public opinion shifted for many reasons, but one case did disproportionate work.

Charlotte Figi was a Colorado child with Dravet syndrome, a severe treatment-resistant epilepsy. Her family’s use of a high-CBD, low-THC cannabis extract, and the reported reduction in her seizures, received national coverage in 2013. The strain was renamed Charlotte’s Web.

The effect on policy was rapid and specific: a wave of states that had shown no interest in broad medical cannabis passed narrow CBD-only laws. It also refocused attention on CBD as distinct from THC and, importantly, on product consistency — families were dosing a child with an unregulated preparation, and that made composition testing a mainstream concern rather than a technical one. The fuller account is in Charlotte Figi and the turning point for CBD.

Hemp Splits Off

The 2018 Farm Bill removed hemp — cannabis containing no more than 0.3% delta-9 THC by dry weight — from the Controlled Substances Act.

That created two parallel legal categories for what is botanically one plant, distinguished by a threshold. It also created the CBD retail market and, less intentionally, a market in hemp-derived intoxicating cannabinoids that the drafters did not anticipate.

Missouri’s Route

Missouri legalized medical cannabis by ballot initiative in November 2018 — Amendment 2 — and wrote the framework into the state constitution rather than leaving it to the legislature. That framework was capped from the start: no more than twenty-four dispensary licenses per congressional district, with minimum cultivation and manufacturing counts tied to population. Testing facilities were deliberately left uncapped.

Amendment 3 followed in November 2022, adding adult use and converting existing medical licensees, with the first adult-use sales in February 2023. Testing rules were codified at 19 CSR 100-1.110, which requires laboratories to hold ISO/IEC 17025 accreditation within a year of approval and to pass annual proficiency testing.

The tightening since has been about ownership and supply rather than access. Microbusiness rules were revised in 2026 after licenses were revoked over ownership arrangements, and legislation signed in April 2026 reclassified intoxicating hemp products as marijuana, restricting them to licensed dispensaries from November 2026.

That arc — a framework written at the ballot box, expanded by a second vote, then tightened around ownership and product scope — is a common pattern across states that legalized by initiative.

What the History Suggests

Two things stand out.

First, cannabis was regulated out of medicine largely for reasons unrelated to evidence, and rebuilding an evidence base has taken decades — partly because Schedule I made the research itself difficult. That is why the state of the evidence is patchier than the length of the plant’s medical history would suggest. See the science behind medical cannabis research.

Second, the nineteenth-century problem and the modern one are the same problem. Cannabis preparations varied unpredictably in strength, which limited their clinical usefulness then and drives the testing requirements now. The difference is that we can now measure what is in a product. That capability is what separates a regulated cannabis market from an unregulated one — as much as any statute.

The post From the Marihuana Tax Act to Amendment 3: A History of Cannabis Regulation appeared first on TruMo Analytics.

The Core Problem

Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act. Banks are federally regulated and federally insured, which means federal law governs what they can do regardless of what any state permits.

Handling money from cannabis sales exposes a bank to potential money laundering liability, because the underlying activity is federally illegal. That exposure applies whether or not the business is fully licensed and compliant under state law.

Card networks operate on the same logic. Visa and Mastercard prohibit processing for federally illegal transactions, which is why standard card payment is unavailable at most dispensaries.

Why Some Banks Participate Anyway

A minority do. FinCEN guidance issued in 2014 set out how a financial institution can serve cannabis businesses while meeting its Bank Secrecy Act obligations — essentially through enhanced due diligence and specific suspicious activity reporting.

That gives a compliance path, and some credit unions and smaller regional banks have taken it. The compliance burden is heavy, though: ongoing verification of license status, monitoring for red flags, and continuous reporting. Institutions that do this charge accordingly, with monthly account fees that dwarf ordinary business banking.

Most large banks have concluded the exposure is not worth it, which is why availability remains thin and expensive.

What Cash-Only Actually Costs

The consequences go well beyond inconvenience.

Security. Businesses holding significant cash on site are targets. Dispensaries invest heavily in safes, armoured transport, guards and surveillance — costs that a card-accepting retailer does not carry.

Employee risk. Staff handling large cash volumes are exposed in a way retail workers generally are not.

Accounting burden. Cash reconciliation at volume is labour-intensive and error-prone, and cannabis businesses already carry heavy compliance record-keeping.

Tax payment. Businesses without bank accounts have had to pay substantial tax bills in cash, which imposes cost and risk on the tax authority as well.

Capital access. Without banking relationships, conventional lending is largely unavailable. Cannabis businesses rely on private capital at higher cost, which shapes who can enter the industry and at what scale. That connects directly to the ownership concentration discussed in diversity, equity and inclusion in the cannabis industry.

Transparency. The irony is that cash-heavy operations are harder to audit than banked ones. A policy intended to limit illicit activity produces a sector where money movement is less traceable.

The Workarounds, and Their Limits

Cashless ATM / point-of-banking. The transaction is structured as an ATM withdrawal at the register, rounded to a fixed increment, with the difference given as change. Widely used, and repeatedly the subject of network enforcement — several major processors have shut these arrangements down.

PIN debit. Some processors route debit transactions through networks with different rules. Availability fluctuates.

ACH and closed-loop apps. Bank transfer-based payment apps where customers preload funds. Legitimate but adoption-limited.

On-site ATMs. The most common solution. Customers withdraw cash inside the dispensary, with fees.

The recurring pattern is that workarounds are fragile. Arrangements that operate for a year get shut down when a network notices, and the business is back to cash.

What Would Change It

SAFE Banking legislation. Proposed in various forms across multiple sessions of Congress, it would provide a safe harbour for financial institutions serving state-legal cannabis businesses. It has passed the House more than once without becoming law. It would address banking specifically without changing cannabis’s scheduling.

Rescheduling or descheduling. Moving cannabis out of Schedule I would address the underlying cause rather than the symptom, and would affect banking, taxation, research and regulation together.

State-level workarounds. Some states have explored state-chartered financial institutions for cannabis. These face the same federal constraints, since payment infrastructure ultimately connects to federally regulated systems.

The banking problem is one of the clearest illustrations of what federal-state conflict produces: a fully licensed, taxed, regulated industry that cannot use ordinary financial infrastructure. More on where reform might go in the future of the cannabis industry, and on the origins of the federal position in from the Marihuana Tax Act to Amendment 3.

Practical Notes

For customers: bring cash. Withdraw before you arrive if you want to avoid ATM fees. Expect payment options to change between visits.

For operators: treat cash handling as a security and compliance discipline, not an inconvenience. Document everything — cash-intensive businesses attract scrutiny, and clean records are the defense. If you can secure a banking relationship, the fees are usually worth it for the audit trail alone. And be cautious with payment workarounds that sit in a gray area, because they tend to end abruptly.

The post Why Cannabis Dispensaries Still Operate in Cash appeared first on TruMo Analytics.